M600 Innovation Hub: A space for life-science companies
Originally developed by CSL as part of its long-standing Marburg operations, the M600 R&D Campus is opening its doors to new tenants and evolving into an open-innovation environment for a broader life-science community.
Laboratory, technical, and office space is available now - for biotech companies, research organisations, CROs, CDMOs, and innovation-driven businesses looking to establish themselves in an operating biopharmaceutical environment.
- 40000 m2
of laboratory, technical & office space
- 7,800 m2
of laboratory space across five areas
- BSL-1-3
biosafety levels, plus separate pilot plant
- .
.
- 7,200
life-science professionals in the cluster
- .
.
A curated multi-tenant campus
Unlike a conventional multi-tenant building, M600 is being curated for strategic fit across its tenants. It brings together academia, start-ups, CROs/CDMOs and biopharmaceutical companies, so that scientists and industry experts work side by side within the same building and across the campus.
The full development chain, on one campus
M600 gives tenants direct access to capabilities that would otherwise require significant time and capital to build independently.
| Early-stage research Stage 1 |
Access to technical platforms and laboratories from day one. |
| IND/IMPD readiness Stage 2 |
Preclinical development through to regulatory submission readiness |
| Pilot-scale Stage 3 |
Production-scale development in the separate on-site pilot plant. |
| GMP scale-up Stage 4 |
GMP manufacturing potential on campus, without outsourcing. |
Within Europe's pandemic-preparedness cluster
Unique scientific infrastructure
Philipps University Marburg operates a BSL-4 facility - the highest biosafety classification and unique among German universities - researching highly pathogenic viruses for which no vaccines or therapies yet exist.
Growing preparedness capacity
A new BSL-4 laboratory, the Marburg Centre for Epidemic Preparedness (MCEP), is under construction and scheduled for completion by the end of 2026, backed by roughly €46 million in federal and state funding.
Connected to a European initiative
The university is an affiliated entity of the European Vaccines Hub for Pandemic Readiness, a pan-European public-private partnership co-funded by the European Commission under DG HERA.
Infrastructure that lets you focus on the science
The laboratory area covers biosafety levels BSL-1 to BSL-3, with a separate pilot plant supporting clinical-scale research. Full on-site facility management - including pharma-specific services, site security, and environmental management - is in place, so incoming organisations can focus on science immediately.
For tenants, this means access not only to infrastructure, but to an established network of peers, suppliers, and potential collaborators - the environment in which early-stage research can scale faster.
Available space
Office & laboratory space in the R&D campus available now, divisible into smaller units, commission-free and accessible. Rents and square meters on request.
Facilities & data
| Total usable area | 40,000 m2 |
| Laboratory space | 7,800 m,2 divided into five areas (G2-G6) |
| Safety classification | GenTSV S1/S2 · biosafety BSL-1 to BSL-3 |
| Pilot plant | Separate pilot plant for plasma products, production-scale |
| Availability | Short-term · divisible into smaller units |
On-site services
- Full facility management
- Laboratory services and pharma-specific expertise
- Site security and on-site fire brigade
- Environmental management and waste handling
- Flexible office space with app-bookable workstations
- Conference rooms, cafeteria and quiet zones